Pulmonary Artery Pressure Sensor-Guided Therapy for Cardiac AL Amyloidosis in a Young Multiple Myeloma Patient
Abstract
Background: Volume assessment in cardiac amyloid light chain (AL) amyloidosis is challenging during high-dose chemotherapy and autologous stem cell transplantation (SCT), as clinical findings and body weight may not accurately reflect intravascular congestion.
Case summary: A 45-year-old man with multiple myeloma, nephrotic syndrome, and cardiac AL amyloidosis developed marked volume fluctuations during induction therapy. Before SCT, an implantable pulmonary artery pressure (PAP) sensor was placed to guide diuretics, targeting a diastolic PAP of 22 mm Hg. During the peritransplant period, remote PAP monitoring enabled individualized diuretic titration despite mucositis, gastrointestinal losses, transfusions, neutropenic fever, delirium, and weight variation. He completed SCT without heart failure decompensation and achieved complete hematologic remission.
Discussion: This case highlights the value of PAP-guided management in complex cardio-oncology patients with dynamic hemodynamics.
Take-home messages: In cardiac AL amyloidosis, invasive hemodynamic monitoring may outperform clinical assessment. PAP-guided management may be useful during SCT when risks of congestion and hypovolemia coexist.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.